Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 250

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 250
---
520,056 Public Shares are redeemed. (4)Corresponds to 3,342,188 Company Shares to be issued to Sponsor. (5)Corresponds to 970,312 Company Shares to be issued to the Initial Sponsor. (6)The number of shares corresponding to the Public Shareholders includes the effects of redemptions after June 30, 2024, described in footnote (1) under “ Adjustments to Unaudited Pro Forma Combined Consolidated Statement of Financial Position as of June 30, 2024.” (7)Prior to Closing, the Parent expects to redeem 62,500 Parent shares held by Theo, and Theo expects to subsequently distribute a total of 1,500,000 Company Shares to between 300 and 424shareholders of Bioceres S.A. and Bioceres Group, which is consistent with Bioceres Group PLC’s policy to distribute shares of its investees to its limited partners, so that they hold shares directly, and not through any investment vehicle. (8)Company Shares issued to Theo pursuant to the Backstop Agreement assuming that it satisfies its obligations thereunder pursuant to the subscription of up to 1,000,000 Company Shares at an issue price of $10.00 per Company Share (par value of $0.0001) and making a cash contribution in an amount of up to $10,000,000 that exceeds the aggregate amount of cash on deposit in the Trust Account (including any interest earned on the funds held in the Trust Account) remaining after payment in full of the SPAC Shareholder Redemption Amount. See “ Questions and Answers about the Business Combination and the Special Meeting — Q. What equity stake will our current shareholders and shareholders of the Target hold in OmnigenicsAI immediately after consummation of the Business Combination” and “ Certain Agreements Related to the Business Combination — Backstop Agreement.”

115 The Special Meeting of SPAC Shareholders General APx is furnishing this proxy statement/prospectus to its shareholders as part of the solicitation of proxies by the APx Board for use at the Special Meeting to be held on, 2025, and at any postponements or adjournments thereof. This proxy statement/prospectus is first being furnished to APx’s shareholders on or about, 2025 in connection with the vote on the proposals described in this proxy statement/prospectus. This proxy statement/prospectus provides APx’s shareholders with information they need to know to be able to vote or